Nahdi Medical Company · TADAWUL:4164
Nahdi Medical — Q1 2025 Earnings Presentation
20 slides from Nahdi Medical's earnings presentation, 2025
Slide 1: Nahdi Medical Company Investor Presentation Q1 2025
Nahdi Medical Company INVESTOR PRESENTATION Q1 2025 Nahdi Medical Company | Q1 2025
Slide 2: Financial Highlights
Financial Highlights Nahdi Medical Company | Q1 2025
Slide 3: Q1 2025 Financial Highlights
Q1 2025 Financial Highlights Revenue 2.64bn 16.7% 2.26bn RESILIENT FINANCIAL Gross Profit 951mn (36.1%) 10.5% 861mn (38.1%) PERFORMANCE Operating Profit 270mn (10.2%) 16.6% 232mn (10.3%) Net Profit 255mn (9.7%) 9.5% 233mn (10.3%) Capex EPS STRONG CASH FLOW ZERO DEBT 3.9% of revenue 1.96 9.5% GENERAT
Slide 4: Solid Revenue Growth Across Businesses & Categories
Solid Revenue Growth Across Businesses & Categories Pharmacies 1,120 1,181 1,162 1,202 Revenue in Q1 2025 grew by 16.7% YoY driven by strong performance Clinics 6 10 7 11 across all business segments Retail business rose by 15.2% mn supported by double-digit growth in both Pharma & Front Shop segmen
Slide 5: Diversified Sales Channel Growth Driving Top-Line Acceleration
Diversified Sales Channel Growth Driving Top- Line Acceleration mn 3,000 +15.2% +76.4% +44.0% +16.7% Retail Segment led the growth 2,500 by delivering 15.2% YoY growth 2,257 supported by double-digit growth in both Pharma & Front 2,000 Shop segments Accelerated growth in the 1,500 97% 95% Healthcare
Slide 6: Operating Margin Stability Driven By OPEX Efficiencies
Operating Margin Stability Driven By OPEX Efficiencies Compensating For Gross Margin Compression The margin compression was 45.0% primarily driven by accelerated 38.1% growth in the Healthcare and online 36.1% 2% Decline businesses, which operate not only with lower gross margins but also benefit fr
Slide 7: Best in Class Operating Profit Margin
Operating Best in Class Operating Profit Margin Operating profit grew by 16.6%, in Margin 11.0% 9.2% 10.3% 10.2% line with top-line growth reaching 270 million, representing 10.2% margin mn Operating Profit 16.6% Source: Company disclosure Nahdi Medical Company | Q1 2025
Slide 8: Attractive Net Profit Profile
Net Profit/ Attractive Net Profit Profile Net profit grew by 9.5%, Revenue 10.2% 8.7% 10.3% 9.7% reaching 255 million, representing 9.7% margin mn Non-operating items increased by 28 million mainly due to higher financial charges and lease Net Profit liability interest to support revenue growth and
Slide 9: Guidance
Guidance Q1 2025 2025 Guidance Actuals Total revenue Revenue growth 16.7% Growth (6% - 8%) EPS EPS Expected to grow 9.5% annually at (4% - 6%) Capex Capex 3.9% (~4%) Expected to Dividend Policy continue at 87% in 2024 (70% - 80%) Growth to be funded Zero Debt Capital Structure organically Nahdi Medi
Slide 10: Strategy & Operational Review
Strategy & Operational Review Nahdi Medical Company | Q1 2025
Slide 11: Guest Satisfaction - the Cornerstone of our strategy
Nahdi: Guest Satisfaction - the Cornerstone of our strategy Stronger Brand Equity YoY Nielsen Store Equity Index ** 65% of revenue generated from Nahdi “Nuhdeek” Guests* 90 NPS Source: Company disclosure, Nielsen By End of Q1 2025 **Methodology used to identify the brand equity of pharmacies and und
Slide 12: Always Delivers Value to Our Guests
Our Passion for People Always Delivers Value to Our Guests 35 % More than 500K hours of training conducted annually Hiring +1000 national pharmacists Human Resource Development Fund 24 Universities. providing 2,000+ training opportunities Among the top companies in Saudi, GCC, Middle East and Asia f
Slide 13: Ramadan; a New Seasonal Record For Nahdi in Q1 2025
Ramadan; a New Seasonal Record For Nahdi in Q1 2025 Nahdi App Total Downloads Revenue 847,000 Nahdi Home App Deliveries +16.7% Nahdi Medical Company | Q1 2025
Slide 14: Strategic Initiatives
Strategic Initiatives Nahdi Medical Company | Q1 2025
Slide 15: Digital Acceleration: Seamless Experiences to Fuel Q1 2025 Growth
Digital Acceleration: Seamless Experiences Highest ever Nahdi Online contribution in to Fuel Nahdi’s Q1 2025 Growth Online sales with Q1 2025 from Revenue total business 35% 24% vs Q1 2024 vs 20% Q1 2024 Nahdi Global a key driver in Nahdi Online Q1 2025 items listed Revenue +104% +158% Over Q1 2024
Slide 16: Nahdi's Private Label Powerhouse; Delivering Growth & Guest Loyalty
Nahdi’s Private Label Powerhouse; Delivering Growth & Guest Loyalty ▪ Exceptional Growth: Q1 2025 Revenue +47% with Revenue Contribution 16% vs.12% Q1 2024 ▪ Strong Customer Loyalty; PL products: 93% retention vs. 79% for regular products ▪ Partnered with 8 local medicine manufacturers & introduced
Slide 17: Nahdi's Leap: Advancing National Healthcare Leadership
Nahdi’s Leap: Advancing National Healthcare Leadership ▪ Opened 1 Nahdicare Clinic in Riyadh city in Q1 2025 reaching a total of 11 clinics across KSA ▪ Q1 2025 Clinics business served 481K guests (walk-in & virtual) +44% vs Q1 2024 ▪ Clinics business demonstrates exceptional growth, Q1 2025 Revenue
Slide 18: Strategic Expansion in UAE; A Robust Platform for Regional Growth
Nahdi's Strategic Expansion in UAE; A Robust Platform for Regional Growth ▪ Strong growth Q1 2025 Revenue 44% vs. Q1 2024 & added 5 new pharmacies totaling 30 in UAE ▪ Broad geographic coverage with presence in major Emirates, which strengthens our reach Ras Alkhaimah ▪ Established Best-in-class dis
Slide 19: Pharmacy Retail Healthcare & Regional
the CORE SEED the FUTURE Lead Accelerate Healthcare & Regional Pharma GUESTS Pharmacy Retail Healthcare - Payers Expansion - Providers at heart - Dispensing Excellence UAE Expansion Grow Innovate Front Shop - Fair Value - Medical Adherence - Assortment & New Journey Categories - AI Hyper Personaliza
Slide 20: Thank You
Thank You Investor Relations Department Contacts: Website: https://investors.nahdi.sa/ Email: IR@nahdi.sa Phone: +966 556 315 822 Nahdi Medical Company | Q1 2025
Nahdi Medical Company — Q1 2025 Earnings Presentation on 6ix